MA53481A - Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde - Google Patents

Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Info

Publication number
MA53481A
MA53481A MA053481A MA53481A MA53481A MA 53481 A MA53481 A MA 53481A MA 053481 A MA053481 A MA 053481A MA 53481 A MA53481 A MA 53481A MA 53481 A MA53481 A MA 53481A
Authority
MA
Morocco
Prior art keywords
compositions
methods
rheumatoid arthritis
treating subjects
subjects
Prior art date
Application number
MA053481A
Other languages
English (en)
Inventor
Anita Boyapati
Neil Graham
Toshio Kimura
Jérôme Msihid
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA53481A publication Critical patent/MA53481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
MA053481A 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde MA53481A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US201962858443P 2019-06-07 2019-06-07
EP19192387 2019-08-19

Publications (1)

Publication Number Publication Date
MA53481A true MA53481A (fr) 2021-07-07

Family

ID=67851236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053481A MA53481A (fr) 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Country Status (16)

Country Link
US (2) US11319375B2 (fr)
EP (1) EP3843852A1 (fr)
JP (1) JP7504871B2 (fr)
KR (1) KR20210049871A (fr)
CN (1) CN112955222A (fr)
AU (2) AU2019329958B2 (fr)
BR (1) BR112021003206A2 (fr)
CA (1) CA3110891A1 (fr)
CL (1) CL2021000483A1 (fr)
IL (1) IL280824A (fr)
MA (1) MA53481A (fr)
MX (2) MX2021002422A (fr)
PH (1) PH12021550416A1 (fr)
SG (1) SG11202101674QA (fr)
TW (2) TW202532441A (fr)
WO (1) WO2020047029A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
FR3095698B1 (fr) * 2019-05-03 2021-05-07 Sinnovial Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
IL298088A (en) * 2020-05-26 2023-01-01 Sanofi Biotechnology The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (fr) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Proteine du recepteur du facteur d'induction des cellules humaines b2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA2736076A1 (fr) 1991-03-18 1992-09-19 New York University Anticorps monoclonaux et chimeriques specifiques du facteur de necrose tumorale humain
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
WO2001027116A2 (fr) 1999-10-07 2001-04-19 Eli Lilly And Company Composes et procedes permettant d'inhiber la mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
CA2565714C (fr) 2004-05-06 2014-12-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Processus et compositions pour le traitement de l'uveite
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010106812A1 (fr) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Formulation pharmaceutique contenant des molécules d'anticorps améliorées
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2464666B1 (fr) * 2009-07-15 2018-03-21 Eva Kovacs-Benke Combinaison d'un antagoniste de l'interleukin 6 humaine et d'unantagoniste du récepteur humain de l'interleukin 6 pour le traitement des maladies tumorales
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011140522A1 (fr) 2010-05-07 2011-11-10 Xoma Technology Ltd. Méthodes de traitement d'affections associées à l'il-1β
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
EP2670438A4 (fr) * 2011-02-03 2015-05-20 Santarus Inc Sélection et traitement de patients
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
EP3042202A1 (fr) * 2013-09-03 2016-07-13 Graham, L. Douglas Procédés de traitement de la polyarthrite rhumatoïde
US20160280782A1 (en) * 2013-11-22 2016-09-29 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2015116852A1 (fr) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la polyarthrite rhumatoïde par l'administration d'un anticorps anti il-6r
PL3193934T3 (pl) 2014-09-16 2021-12-27 Sanofi Biotechnology Kompozycje do poprawiania jakości życia uwarunkowanej stanem zdrowia u pacjentów z reumatoidalnym zapaleniem stawów
SG11201803654TA (en) 2015-11-03 2018-05-30 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
EP3216461A1 (fr) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions et procédés pour le traitement de la polyarthrite rhumatoïde
MX2018010815A (es) 2016-03-07 2019-01-10 Sanofi Biotechnology Composiciones y metodos para tratar artritis reumatoide.

Also Published As

Publication number Publication date
WO2020047029A1 (fr) 2020-03-05
SG11202101674QA (en) 2021-03-30
MX2025010592A (es) 2025-10-01
JP2022502350A (ja) 2022-01-11
CN112955222A (zh) 2021-06-11
AU2019329958B2 (en) 2025-05-29
MX2021002422A (es) 2021-07-15
IL280824A (en) 2021-04-29
KR20210049871A (ko) 2021-05-06
EP3843852A1 (fr) 2021-07-07
BR112021003206A2 (pt) 2021-05-25
CL2021000483A1 (es) 2021-07-19
AU2025203365A1 (en) 2025-05-29
US20200102395A1 (en) 2020-04-02
PH12021550416A1 (en) 2021-09-27
US20230059376A1 (en) 2023-02-23
TW202026035A (zh) 2020-07-16
TWI868074B (zh) 2025-01-01
CA3110891A1 (fr) 2020-03-05
JP7504871B2 (ja) 2024-06-24
TW202532441A (zh) 2025-08-16
US11319375B2 (en) 2022-05-03
AU2019329958A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
EP3399923A4 (fr) Système et méthodes pour le traitement d'une obstruction microvasculaire
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3298140A4 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3801578A4 (fr) Méthodes et compositions pour le traitement de c. difficile
EP3867280A4 (fr) Méthodes de traitement de la polyarthrite rhumatoïde
EP3442541A4 (fr) Méthodes pour traiter le cancer et inhiber le rejet de greffe
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3651795A4 (fr) Compositions et méthodes pour le traitement de cancers présentant une mutation h3k27m
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3399993A4 (fr) Méthodes et compositions pour la prévention et le traitement d'une dystrophie musculaire de duchenne
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3373951A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer
IL280824A (en) Methods and compositions for the treatment of rheumatoid arthritis patients
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer
EP3452044A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3886809A4 (fr) Méthodes et compositions pour le traitement de l'arthrose